DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/hvqdw3/angiogenesis_in) has announced the addition of the "Angiogenesis in Oncology Drug Pipeline Update 2015" report to their offering.
There are today 317 companies plus partners developing 350 angiogenesis drugs in 1693 developmental projects in cancer. In addition, there are 8 suspended drugs and the accumulated number of ceased drugs over the last years amount to another 207 drugs.
Angiogenesis In Oncology Drug Pipeline Update lists all drugs and gives you a progress analysis on each one of them. Identified drugs are linked to 277 different targets. All included targets have been cross-referenced for the presence of mutations associated with human cancer. To date 272 out of the 272 studied drug targets so far have been recorded with somatic mutations.
The software application lets you narrow in on these mutations and links out to the mutational analysis for each of the drug targets for detailed information. All drugs targets are further categorized on in the software application by 59 classifications of molecular function and with pathway referrals to BioCarta, KEGG, NCI-Nature and NetPath.
Pipeline Breakdown According to Number of Drugs
- Marketed - 33
- Registered - 1
- Pre-registration - 3
- Phase III - 54
- Phase II - 156
- Phase I - 178
- Preclinical - 167
- No Data - 11
- Suspended - 8
Ceased - 207
Delivery Format: Desktop App plus Online Access to Updates (One Year)
For more information visit http://www.researchandmarkets.com/research/hvqdw3/angiogenesis_in